Innovative technology ready to deliver new therapy solutions
Current Research areas
The science of Lifesome Therapeutics: The background of Ohmline
Ohmline
as antimicrobial agent
Antibiotic resistance is a main concern among nowadays letal diseases. Lifesome nanotehcnology with intrinsic antimicrobial activity can be used to repurpose antibiotics, tackle antibiotic resistance and improve their therapeutic activity.
Meet the team
Advisory Board
Prof. Thierry Lecomte, MD., PhD.
Oncology Expert
Expert in Hepatogastroenterology and Digestive Oncology
Julio Martin, PhD.
Life Science Expert
Life Science and Pharma R&D expert
Prof. Paul-Alain Jaffres, PhD.
Organic Chemistry, Health and Materials Expert
Lipid chemistry, gene delivery and hybrid materials expertise
Key references
1. Coune A., Sculier J.P., Hildebrand J., Frühling J., Strijkmans P., Brassine C., Ghanem G., Ruysschaert J.-M. and Atassi G.(1983)."Iv administration of a water-insoluble antimitotic compound entrapped in liposomes.Preliminary report on infusion of large volumes of liposomes to man. Cancer Treat. Rep., 67(11): 1031-1033. 2. Bery, F., Cancel, M., Guéguinou, M., Potier-Cartereau, M., Vandier, C., Chantôme, A., Guibon, R., Bruyère, F., Fromont, G., Mahéo, K. (2021). Zeb1 and SK3 Channel Are Up-Regulated in Castration-Resistant Prostate Cancer and Promote Neuroendocrine Differentiation. Cancers, 13, 2947. 3. Bauduin, A., Papin, M., Chantôme, A., Couthon, H., Deschamps, L., Requejo-Isidro, J., ... Vandier, C. & Jaffres, P. A. (2021). Development of pyrene-based fluorescent ether lipid as inhibitor of SK3 ion channels. European Journal of Medicinal Chemistry, 209, 112894. 4. Figiel, S., Bery, F., Chantôme, A., Fontaine, D., Pasqualin, C., Maupoil, V., Vandier, C.... & Mahéo, K. (2019). A novel calcium-mediated EMT pathway controlled by lipids: An opportunity for prostate cancer adjuvant therapy. Cancers, 11(11), 1814. 5. Sevrain, C. M., Fontaine, D., Bauduin, A., Guéguinou, M., Zhang, B. L., Chantôme, A.,...Vandier, C. & Jaffres, P. A. (2021). Thio-ether functionalized glycolipid amphiphilic compounds reveal a potent activator of SK3 channel with vasorelaxation effect. Organic & Biomolecular Chemistry, 19(12), 2753-2766. 6. Rua, C., Guéguinou, M., Soubai, I., Viel, E., Potier-Cartereau, M., Chantome, A., ... & Vandier, C. (2018). SK3 gene polymorphism is associated with taxane neurotoxicity and cell calcium homeostasis. Clinical Cancer Research, 24(21), 5313-5320. 7. Herrera, F. E., Sevrain, C. M., Jaffrès, P. A., Couthon, H., Grélard, A., Dufourc, E. J.,Vandier, C. ... & Bouchet, A. M. (2017). Singular interaction between an antimetastatic agent and the lipid bilayer: The Ohmline case. ACS omega, 2(10), 6361-6370. 8. Guéguinou, M., Felix, R., Marionneau-Lambot, S., Oullier, T., Penna, A., Kouba, S., Bouchet, A. M., Vandier, C.... & Potier-Cartereau, M. (2021). Synthetic alkyl-ether-lipid promotes TRPV2 channel trafficking trough PI3K/Akt-girdin axis in cancer cells and increases mammary tumour volume. Cell Calcium, 97, 102435. 9. Berthe, W., Sevrain, C. M., Chantôme, A., Bouchet, A. M., Gueguinou, M., Fourbon, Y.,Vandier, C. ... & Jaffrès, P. A. (2016). New disaccharide‐based ether lipids as SK3 ion channel inhibitors. ChemMedChem, 11(14), 1531-1539. 10. Papin, M., Bouchet, A. M., Chantôme, A., & Vandier, C. (2023). Ether-lipids and cellular signaling: A differential role of alkyl-and alkenyl-ether-lipids. Biochimie. 11. Lonez, C., Vandenbranden, M., & Ruysschaert, J.-M. (2008). Cationic liposomal lipids: from gene carriers to cell signaling. Progress in lipid research, 47(5), 340-347. 12. Sevrain, C. M., Haelters, J. P., Chantôme, A., Couthon-Gourvès, H., Gueguinou, M., Potier-Cartereau, M., ... Vandier, C.& Jaffrès, P. A. (2013). DiGalactosyl-Glycero-Ether Lipid: Synthetic approaches and evaluation as SK3 channel inhibitor. Organic & Biomolecular Chemistry, 11(27), 4479-4487. 13. Chantôme, A., Potier-Cartereau, M., Clarysse, L., Fromont, G., Marionneau-Lambot, S., Guéguinou, M., ... & Vandier, C. (2013). Pivotal role of the lipid Raft SK3–Orai1 complex in human cancer cell migration and bone metastases. Cancer research, 73(15), 4852-4861. 14. Gueguinou, M., Crottès, D., Chantôme, A., Rapetti-Mauss, R., Potier-Cartereau, M., Clarysse, L., ... Vandier, C. & Soriani, O. (2017). The SigmaR1 chaperone drives breast and colorectal cancer cell migration by tuning SK3-dependent Ca2+ homeostasis. Oncogene, 36(25), 3640-3647. 15. Potier, M., Joulin, V., Roger, S., Besson, P., Jourdan, M. L., LeGuennec, J. Y., ... & Vandier, C. (2006). Identification of SK3 channel as a new mediator of breast cancer cell migration. Molecular cancer therapeutics, 5(11), 2946-2953. 16. Guéguinou, M., Harnois, T., Crottes, D., Uguen, A., Deliot, N., Gambade, A.,Vandier, C. ... & Potier-Cartereau, M. (2016). SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: A novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget, 7(24), 36168. 17. Jaffres, P. A., Gajate, C., Bouchet, A. M., Couthon-Gourves, H., Chantôme, A., Potier-Cartereau, M., ... & Vandier, C. (2016). Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy. Pharmacology & Therapeutics, 165, 114-131. 18. Gueguinou, M., Gambade, A., Félix, R., Chantôme, A., Fourbon, Y., Bougnoux, P., ... & Vandier, C. (2015). Lipid rafts, KCa/ClCa/Ca2+ channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1848(10), 2603-2620. 19. Girault, A., Haelters, J. P., Potier-Cartereau, M., Chantôme, A., Pinault, M., Marionneau-Lambot, S., ... & Vandier, C. (2011). New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis. Current cancer drug targets, 11(9), 1111-1125. 20. Lonez C, Vandenbranden M, Ruysschaert J.-M.. (2012) Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev. 64(15):1749-58.